New Nordic research collaboration to reveal linked mechanisms of age-related fatty liver and muscle loss

A highly competitive award of over 2 million euros from the Novo Nordisk Foundation will support a new research collaboration focused on uncovering the shared metabolic mechanisms linking age-related liver disease and muscle loss.

More than half of over 60-year-olds suffer from more than one chronic disease, reducing their independence and quality of life. Two major factors that increase frailty are fatty liver disease and muscle loss (sarcopenia) affecting hundreds of millions globally. Yet no cure and effective preventive treatments exist. While these processes are well-studied individually, their combined underlying mechanisms remains unknown.

This ambitious project brings together world leading expertise from research groups of Anu Suomalainen Wartiovaara and Thomas McWilliams in the University of Helsinki and Kei Sakamoto in the University of Copenhagen. The teams will draw on their combined experience in molecular metabolism, signaling and cellular quality control to investigate the previously unrecognized biological connection that may help explain why liver and muscle pathology frequently co-occur during aging. The project will combine cutting edge cross-disciplinary approaches from discovery science to translational metabolism.

Uncovering these underlying mechanistic metabolic links may lead to actionable insights and interventions that promote healthy aging and prevent disease progression. 

The new research collaboration between the Novo Nordisk Foundation Center for Basic Metabolic Research (University of Copenhagen) and the SWAN spearhead (Sustainable wellbeing across lifespan) at University of Helsinki, connects leading Nordic researchers to accelerate innovation and train the next generation of scientists. 

CBMR Vice Executive Director Professor Kei Sakamoto, says: “This ambitious and potentially transformative project can only succeed through close collaboration, bringing together synergistic expertise and complementary perspectives on the molecular mechanisms of age-related metabolic disease, across both basic and clinical research. I am excited to build a strong new bridge between research groups in Copenhagen and Helsinki and to deliver novel molecular and translational insights into these conditions.”

SWAN Director, Academy Professor Anu Wartiovaara comments “This project is based on the early synergistic discoveries from the three groups, suggesting that part of metabolic pathways driving two distinct age-relate diseases, fatty liver and muscle wasting, may be shared. We will produce a fundamental understanding of such mechanisms with a high translational potential  for the benefit of patients. I am truly excited to provide our translational and metabolism expertise for this important topic. "

The team’s goal is to together transform the understanding of aging biology and promote healthy aging.